Ajaya Bio is a preclinical-stage biotech company developing BOLT-360™, a bispecific antibody platform with the power to reshape the treatment landscape for autoimmune diseases and oncology. With unmatched specificity, safety, and access to previously untargetable pathways, Ajaya Bio is unlocking new frontiers in patient care.
Lead Program & Pipeline
-
Lead indication: Refractory autoimmune disease
-
Market: ~$4B underserved segment within a ~$30B U.S. market
-
Expanding into additional autoimmune and oncology indications, with 8 advanced candidates in development
Technology Differentiators
-
Biology-first discovery using focused libraries (<100 variants) with rational, biophysics-guided design
-
Precision affinity and avidity engineering informed by structural context, not brute-force screening
-
Native protein conformation modeling enables selective activity in multimeric complexes
-
Proven ability to unlock novel biology for autoimmune disease and cancer
Stage & Investment
-
Stage: Preclinical (lead candidate nomination underway)
-
Funding Raised: ~$350K committed in current bridge round; <$500K total raised
-
Seeking: ~$6M Series A financing for candidate validation, CMC development, and pipeline expansion
-
IP: Three differentiated programs under provisional patents
What's Next
-
Deliver lead candidate with compelling in vivo proof-of-concept data
-
Advance toward IND-enabling studies by 2026
-
Build pharma partnerships and investor momentum
Leadership
Mohit Sachdeva, PhD, MBA
Founder & CEO
Ramesh Singh, PhD
Scientific Lead